Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonidegib and Ruxolitinib in Myelofibrosis
NCT01787552Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- Apr 2018
- Modality
- Allosteric Modulators
- Countries
- 11
01
Overview
A Phase 2 trial of sonidegib in myelofibrosis (MF), sponsored by Novartis. Started May 2013; status: completed.
02
Drugs
sonidegib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01787552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787552.